Allergan Announces First Commercial Use of XEN Glaucoma Treatment System in the US

Source: Allergan

Allergan announced that its XEN Glaucoma Treatment System is now being used by US surgeons to treat refractory glaucoma. The XEN Glaucoma Treatment System, consisting of the XEN45 Gel Stent and the XEN Injector, reduces IOP in patients and is indicated for the management of refractory glaucomas, where previous surgical treatment has failed or in patients with primary open angle glaucoma, and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy.

XEN is implanted through an ab interno approach and reduces IOP by creating a new drainage channel with a permanent implant that becomes flexible when hydrated. More than 12,000 XEN45 Gel Stents have already been distributed worldwide. XEN was cleared by the FDA in November 2016, and is now available, offering a new treatment option for Americans with refractory glaucoma.

“For patients who have experienced unsuccessful treatment with medication, XEN is a welcome new option,” said Robert N. Weinreb, M.D., chair and distinguished professor of ophthalmology and director of the Shiley Eye Institute at the University of California, San Diego.

Related Content